Oramed Pharmaceuticals (ORMP) Competitors $2.12 0.00 (0.00%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$2.19 +0.07 (+3.30%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. ARCT, CRVS, ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, and NGNEShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Oramed Pharmaceuticals (NASDAQ:ORMP) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Does the media prefer ORMP or ARCT? In the previous week, Arcturus Therapeutics had 26 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 29 mentions for Arcturus Therapeutics and 3 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.63 beat Arcturus Therapeutics' score of 0.42 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 0 Very Positive mention(s) 5 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in ORMP or ARCT? 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ORMP or ARCT more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. Oramed Pharmaceuticals' return on equity of -11.34% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -11.34% -10.73% Arcturus Therapeutics -49.26%-24.87%-17.75% Which has more volatility & risk, ORMP or ARCT? Oramed Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Do analysts prefer ORMP or ARCT? Arcturus Therapeutics has a consensus price target of $50.00, indicating a potential upside of 160.01%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, ORMP or ARCT? Oramed Pharmaceuticals has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M64.63-$19.06M-$0.44-4.82Arcturus Therapeutics$152.31M3.43-$80.94M-$2.23-8.62 SummaryOramed Pharmaceuticals beats Arcturus Therapeutics on 9 of the 16 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.59M$10.54B$5.61B$9.84BDividend YieldN/A1.94%4.61%4.07%P/E Ratio-4.8219.6430.2925.74Price / Sales64.6329.26469.53115.79Price / CashN/A24.6838.2159.48Price / Book0.593.088.846.15Net Income-$19.06M$209.94M$3.25B$265.06M7 Day Performance1.44%6.22%3.74%2.60%1 Month Performance1.44%12.43%5.88%2.83%1 Year Performance-9.79%-8.96%30.27%25.58% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals0.754 of 5 stars$2.12flatN/A-5.4%$86.59M$1.34M-4.8210News CoverageEarnings ReportARCTArcturus Therapeutics2.8795 of 5 stars$11.39-4.4%$50.80+346.0%+0.1%$323.01M$152.31M-4.50180Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9514 of 5 stars$4.37+1.4%$15.00+243.2%+39.0%$321.15MN/A-4.3330News CoverageAnalyst RevisionABEOAbeona Therapeutics4.2898 of 5 stars$6.28+0.3%$19.25+206.5%+46.1%$320.24M$3.50M-4.9490News CoverageEarnings ReportOLMAOlema Pharmaceuticals1.7758 of 5 stars$4.57-1.5%$24.50+436.1%-56.2%$317.48MN/A-2.2770News CoverageEarnings ReportAnalyst ForecastALDXAldeyra Therapeutics2.4207 of 5 stars$5.25-0.2%$9.50+81.0%+13.0%$315.05MN/A-6.1810News CoverageInsider TradeAnalyst RevisionAMRNAmarin0.2047 of 5 stars$14.94-0.3%$12.00-19.7%+23.0%$310.40M$228.61M-4.07360BNTCBenitec Biopharma1.7994 of 5 stars$11.90+0.8%$26.00+118.5%+45.0%$309.76M$80K-7.8820News CoverageRCKTRocket Pharmaceuticals4.8795 of 5 stars$2.92+2.1%$16.33+459.4%-83.4%$308.61MN/A-1.16240Analyst RevisionINBXInhibrx Biosciences1.9945 of 5 stars$21.40+1.6%N/A+112.0%$304.86M$200K0.18166News CoverageEarnings ReportShort Interest ↓NGNENeurogene1.9649 of 5 stars$20.35-4.1%$46.17+126.9%-39.8%$302.64M$930K-4.6890News CoverageEarnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies Arcturus Therapeutics Competitors Corvus Pharmaceuticals Competitors Abeona Therapeutics Competitors Olema Pharmaceuticals Competitors Aldeyra Therapeutics Competitors Amarin Competitors Benitec Biopharma Competitors Rocket Pharmaceuticals Competitors Inhibrx Biosciences Competitors Neurogene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access